Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ruxolitinib phosphate Clear all
Recruiting Phase 2 Interventional

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806
View directory record Official record
Conditions
Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Interventions
Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib, Pacritinib, Momelotinib
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Duarte, California • Columbia, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT01787487
View directory record Official record
Conditions
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
Azacitidine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

NCT03654768
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
541
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 6, 2026, 2:21 PM EDT
Active, not recruiting Phase 1 Interventional

CART123 + Ruxolitinib in Relapsed/Refractory AML

NCT06768476
View directory record Official record
Conditions
Relapsed AML, Refractory AML
Interventions
CART123 Cells, Ruxolitinib 10 MG, Ruxolitinib 5 MG
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

NCT01950780
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 6, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

NCT00726232
View directory record Official record
Conditions
Myeloproliferative Neoplasm (MPN)
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 6, 2026, 2:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

NCT07128381
View directory record Official record
Conditions
Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)
Interventions
Axatilimab (SNDX-6352), Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

NCT04370301
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Study of Ruxolitinib in Pancreatic Cancer Patients

NCT01423604
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Ruxolitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
39
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Burbank, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 6, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

NCT03669965
View directory record Official record
Conditions
Polycythemia Vera
Interventions
KRT-232, Ruxolitinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

NCT02475655
View directory record Official record
Conditions
HIV Infections
Interventions
Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 2:21 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 6, 2026, 2:21 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT06008808
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
Interventions
Ruxolitinib, Abatacept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

NCT00509899
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocytosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 6, 2026, 2:21 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase l/II Study of Ruxolitinib for Acute Leukemia

NCT01251965
View directory record Official record
Conditions
Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 2 Interventional

Actuate 1901: 9-ING-41 in Myelofibrosis

NCT04218071
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib, 9-ING-41
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Augusta, Georgia • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 6, 2026, 2:21 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

NCT06233110
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Ruxolitinib, Anagrelide, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 6, 2026, 2:21 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Ruxolitinib in Chronic Hand Dermatitis

NCT05293717
View directory record Official record
Conditions
Chronic Hand Dermatitis
Interventions
Ruxolitinib
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 6, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 6, 2026, 2:21 PM EDT